Johnson Johnson Aktie

199,60 EUR -3,70 EUR -1,82 %

21:16:58

STU

228,00 USD -6,06 USD -2,59 %

21:27:08

BTT

Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.491,35 Mrd. EUR

KGV18,82Div. Rendite2,48%

WKN853260

ISINUS4781601046

SymbolJNJ

Johnson Johnson Aktien News

Sortieren:Datum Meistgelesen

26.02.26EN, Johnson & JohnsonEarly study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

26.02.26EN, Johnson & JohnsonJohnson & Johnson Completes Catheter Portfolio with Launch of CEREGLIDE™ 42, CEREGLIDE™ 57, and INNERGLIDE™ 7

24.02.26EN, Johnson & JohnsonJohnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

WerbungJohnson Johnson-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

23.02.26EN, Johnson & JohnsonSubcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

21.02.26EN, Johnson & JohnsonTREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

19.02.26EN, Johnson & JohnsonRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

18.02.26EN, Johnson & JohnsonJohnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

18.02.26EN, Johnson & JohnsonRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

17.02.26EN, Johnson & JohnsonFDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

07.02.26EN, Johnson & JohnsonJohnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

03.02.26EN, Johnson & JohnsonJohnson & Johnson Highlights New Scientific Evidence and Reinforces its Leadership with Portfolio Advancements at AF Symposium

03.02.26EN, Johnson & JohnsonJohnson & Johnson Releases Report on Surgeon Burnout as More than 40% Surveyed Consider Leaving the Profession

27.01.26EN, Johnson & JohnsonDARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

27.01.26EN, Johnson & JohnsonJohnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

21.01.26EN, Johnson & JohnsonJohnson & Johnson reports Q4 and Full-Year 2025 results

16.01.26EN, Johnson & JohnsonNew clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder

15.01.26EN, Johnson & JohnsonJohnson & Johnson Introduces Mobile Simulator App to Support Breast Augmentation Patients

13.01.26EN, Johnson & JohnsonJohnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

10.01.26EN, Johnson & JohnsonRYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

10.01.26PR NewswireRYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

09.01.26EN, Johnson & JohnsonJohnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

08.01.26EN, Johnson & JohnsonJohnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award

07.01.26EN, Johnson & JohnsonJohnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

06.01.26EN, Johnson & JohnsonJohnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

06.01.26PR NewswireJohnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

29.12.25EN, Johnson & JohnsonJohnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

22.12.25EN, Johnson & JohnsonEuropean Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

19.12.25EN, Johnson & JohnsonJohnson & Johnson Backs HRS Registry to Advance Real-World Evidence in PFA

18.12.25EN, Johnson & JohnsonJohnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

18.12.25PR NewswireJohnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

18.12.25PR NewswireU.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (la...

13.12.25EN, Johnson & JohnsonU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

13.12.25PR NewswireU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

09.12.25PR NewswireUnprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multip...

06.12.25PR NewswireEarlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

06.12.25EN, Johnson & JohnsonEarlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

05.12.25EN, Johnson & JohnsonJohnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

05.12.25PR NewswireJohnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

03.12.25EN, Johnson & JohnsonJohnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.